Weight loss from obesity drugs may not lead to broader health benefits - Health Care Today

Most obesity drugs do not improve quality of life or heart health

Despite substantial weight loss, most obesity drugs such as Wegovy and Mounjaro do not meaningfully improve quality of life, and few show cardiovascular benefits at one year, according to an analysis of the latest evidence published by The British Medical Journal (BMJ).More weight loss is also generally accompanied by greater harms, including stomach and bowel symptoms, fatigue and loss of lean (muscle) mass, and improvements are not sustained a…

Weight loss from obesity drugs may not lead to broader health benefits - Health Care Today

While obesity drugs can lead to substantial weight loss, the average weight reduction after 1 year can vary widely between drugs. Additionally, medications linked to larger reductions in body weight were also associated with more side effects, including gastrointestinal symptoms, fatigue, treatment discontinuation, and loss of lean muscle mass. The review found no convincing evidence that most obesity medications improved quality of life or redu…